1. Antibodies
  2. Homo sapiens
  3. TNRC6A

ENCAB000BGD

Antibody against Homo sapiens TNRC6A

Homo sapiens
K562, HepG2
partially characterized
Homo sapiens
at least one cell type or tissue
not pursued
Status
released
Source (vendor)
MBLI
Product ID
RN033P
Lot ID
001
Characterized targets
TNRC6A (Homo sapiens)
Host
rabbit
Clonality
polyclonal
Purification
affinity
Antigen description
KLH conjugated synthetic peptide, corresponding to internal region of human TNRC6A
External resources

Characterizations

TNRC6A (Homo sapiens)
HepG2
Method: immunoprecipitation
Attachment from submitter
Attachment from submitters
compliant
Caption
IP-Western Blot analysis of HepG2 whole cell lysate using TNRC6A specific antibody. Lane 1 is 1% of twenty million whole cell lysate input and lane 2 is 25% of IP enrichment using rabbit normal IgG (lanes under 'IgG'). Lane 3 is 1% of twenty million whole cell lysate input and lane 4 is 10% IP enrichment using rabbit polyclonal anti-TNRC6A antibody (lanes under 'TNRC6A').
Submitted by
Steven Blue
Lab
Gene Yeo, UCSD
TNRC6A (Homo sapiens)
K562
Method: immunoprecipitation
Attachment from submitter
Attachment from submitters
compliant
Caption
IP-Western Blot analysis of K562 whole cell lysate using TNRC6A specific antibody. Lane 1 is 1% of twenty million whole cell lysate input and lane 2 is 25% of IP enrichment using rabbit normal IgG (lanes under 'IgG'). Lane 3 is 1% of twenty million whole cell lysate input and lane 4 is 10% IP enrichment using rabbit polyclonal anti-TNRC6A antibody (lanes under 'TNRC6A').
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD
TNRC6A (Homo sapiens)
Method: immunoprecipitation
Attachment from submitter
Attachment from submitters
not submitted for review by lab
Caption
IP-WB characterization of TNRC6A specific antibody in K562 cell line . Lane 1 is 2.5% of five million K562 whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-TNRC6A(GW182)(Human)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD